Humana (HUM) Set to Announce Quarterly Earnings on Wednesday

Humana (NYSE:HUM) is set to release its earnings data before the market opens on Wednesday, April 24th. Analysts expect Humana to post earnings of $6.06 per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Humana (NYSE:HUM) last released its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.76 by ($0.87). The company had revenue of $26.46 billion during the quarter, compared to the consensus estimate of $25.47 billion. Humana had a return on equity of 19.44% and a net margin of 2.34%. The company’s revenue was up 17.9% on a year-over-year basis. During the same period in the previous year, the firm posted $1.62 earnings per share. On average, analysts expect Humana to post $16 EPS for the current fiscal year and $23 EPS for the next fiscal year.

Humana Trading Up 0.9 %

HUM opened at $317.42 on Wednesday. The firm has a market cap of $38.30 billion, a price-to-earnings ratio of 16.02, a PEG ratio of 1.83 and a beta of 0.45. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.63. Humana has a 12 month low of $299.23 and a 12 month high of $541.21. The stock has a fifty day moving average price of $345.31 and a 200-day moving average price of $426.43.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Friday, March 29th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.12%. The ex-dividend date is Wednesday, March 27th. Humana’s payout ratio is 17.86%.

Analysts Set New Price Targets

Several research analysts have recently commented on HUM shares. Cantor Fitzgerald reissued a “neutral” rating and issued a $391.00 price target on shares of Humana in a research report on Wednesday, April 10th. StockNews.com lowered Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 26th. Oppenheimer reaffirmed an “outperform” rating and set a $630.00 target price on shares of Humana in a research report on Wednesday, January 17th. Wells Fargo & Company reduced their target price on Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research report on Monday, April 8th. Finally, TheStreet lowered Humana from a “b” rating to a “c+” rating in a research report on Monday, January 8th. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $465.42.

Insider Buying and Selling

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was bought at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the transaction, the director now owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.29% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. FIL Ltd boosted its position in shares of Humana by 8.0% during the fourth quarter. FIL Ltd now owns 256,410 shares of the insurance provider’s stock worth $117,387,000 after buying an additional 18,903 shares during the period. SageView Advisory Group LLC purchased a new position in Humana in the fourth quarter valued at $652,000. Sanibel Captiva Trust Company Inc. purchased a new position in Humana in the fourth quarter valued at $1,470,000. Harbour Investments Inc. boosted its holdings in Humana by 51.8% in the fourth quarter. Harbour Investments Inc. now owns 346 shares of the insurance provider’s stock valued at $158,000 after purchasing an additional 118 shares during the period. Finally, GSA Capital Partners LLP purchased a new position in Humana in the fourth quarter valued at $2,297,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.